The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 89-97

  Sugimoto, Yoshiyuki ^a   Hirota, Maiko ^a   Yoshikawa, Kazuhiro ^b   Sumitomo, Makoto ^b   Nakamura, Kogenta ^b   Ueda, Ryuzo ^b   Niwa, Rinpei ^a   Suzawa, Toshiyuki ^a   Yamasaki, Motoo ^a   Shitara, Kenya ^a   Kato, Takashi ^c   Nakamura, Kazuyasu ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c WASEDA UNIVERSITY   (Japan)

Author keywords

Antibodydependent cellular cytotoxicity; IL 2; Immunocytokine; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

ANTIBODY CONJUGATE; CHIMERIC ANTIBODY; CHIMERIC ANTIBODY KM2777; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY; RECOMBINANT CYTOKINE; RECOMBINANT CYTOKINE KM2812; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; PSMA PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG SCREENING; FLOW CYTOMETRY; IL-2; IMMUNOCYTOKINE; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PROSTATE TUMOR; PROSTATE-SPECIFIC MEMBRANE ANTIGEN; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL CULTURE;

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; IL-2; IMMUNOCYTOKINE; PROSTATE CANCER; PROSTATE-SPECIFIC MEMBRANE ANTIGEN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, SURFACE; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897020685     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Siegel R, Naishadham D and Jemal A: Cancer Statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, Cookson MS, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Howe RJ, Lange PH, Lilja H, Loughlin KR, Mohler J, Moul J, Nadler RB, Patterson SG, Presti JC, Stroup AM, Wake R and Wei JT: NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 8: 162-200, 2010.
3. Aggarwal R and Ryan CJ: Castration-resistant prostate cancer: Targeted therapies and individualized treatment. Oncologist 16: 264-275, 2011.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med 351: 1502-1512, 2004.
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Eng J Med 351: 1513-1520, 2004.
6. Mathew P and DiPaola R: Taxane-refractory prostate cancer. J Urol 178: S36-41, 2007.
7. Welner LM, Murray JC and Shuptrine CW: Antibody-based immunotherapy of cancer. Cell 148: 1081-1084, 2012.
8. Israeli RS, Powell CT, Corr JG, Fair WR and Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994.
9. Wright GL Jr., Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF and Moriarty R: Up-regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-334, 1996.
10. Bostwick DG, Pacelli A, Blute M, Roche P and Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 82: 2256-2261, 1998.
11. Sweat SD, Pacelli A and Murphy GP: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52: 637-640, 1998.
12. Kato K, Yoshikawa K, Taki T, Shitara K, Nakamura K, Hirota M, Hanai N, Nakamura K, Kokubo H, Mitsui K, Yamada Y, Honda N, Ueda R, Saga S and Fukatsu H: Further investigation of the epitope recognized by the new monoclonal antibody 2C9. Int J Urol 10: 439-444, 2003.
13. Ortiz-Sanchez E, Helguera G, Daniels TR and Penichet ML: Antibody-cytokine fusion proteins: Applications in cancer therapy. Expert Opin Biol Ther 8: 609-632, 2008.
14. Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmilevich A, Hank JA, Gillies SD and Sondel PM: Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother 48: 219-229, 1999.
15. Becker JC, Pancook JD, Gillies SD, Furukawa K and Reisfeld RA: T-Cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183: 2361-2366, 1996.
16. Becker JC, Varki N, Gillies SD, Furukawa K and Reisfeld RA: An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 93: 7826-7831, 1996.
17. Becker JC, Varki N, Gillies SD, Furukawa K and Reisfeld RA: Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 98: 2801-2804, 1996.
18. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD and Reisfeld RA: Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Proc Natl Acad Sci USA 95: 2475-2480, 1998.
19. Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X, Lo KM, Lan Y, Super M, Gillies SD and Reisfeld RA: Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 57: 4948-4955, 1997.
20. Xiang R, Lode HN, Gillies SD and Reisfeld RA: T-Cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 163: 3676-3683, 1999.
21. Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD and Sondel PM: The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61: 1500-1507, 2001.
22. Holden SA, Lan Y, Pardo AM, Wesolowski JS and Gillies SD: Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 7: 2862-2869, 2001.
23. Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD and Sondel PM: Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10: 4839-4847, 2004.
24. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD and Sondel PM: A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group. Clin Cancer Res 12: 1750-1759, 2006.
25. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD and Sondel P: Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22: 4463-4473, 2004.
26. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T and Gillies SD: Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): Results of a phase I trial in patients with prostate cancer. J Immunother 27: 232-239, 2004.
27. Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD and Sondel P: Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 27: 211-219, 2004.
28. Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K and Hanai N: Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol 37: 1035-1046, 2000.
29. Li B, Zhao L, Guo H, Wang C, Zhang X, Wu L, Chen L, Tong Q, Qian W, Wang H, Guo Y: Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 114: 5007-5015, 2009.
30. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ and Olson WC: Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 12: 2591-2596, 2006.
31. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ and Bander NH: Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22: 2522-2531, 2004.
32. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S and Goldsmith SJ: Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostatespecific membrane antigen, in patients with androgenindependent prostate cancer. J Clin Oncol 23: 4591-4601, 2005.
33. Kantoff P, Petrylak DP, Pomerantz M, Israel RJ, Olson WC, Ramakrishna T and Morris S: First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer. ASCO Annu Meet Abstract no. TPS245, 2010.
34. Petrylak DP, Kantoff PW, Frank RC, Shore ND, Rotshteyn Y, Israel RJ, Olson WC, Ramakrishna T and Morris S: Prostatespecific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. ASCO Annu Meet Abstract no.4650, 2011.
35. Petrylak DP, Kantoff PW, Mega AE, Dreicer R, Frank RC, Shore ND, Morris S, Olson WC and Israel RJ: Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. ASCO Genitourinary Cancer Symp Abstract no. 107, 2012.
36. Mega AE, Petrylak DP, Kantoff P, Stephenson J, Vogelzang NJ, Dreicer R, Shore ND, Stambler N, Carpenito J, D'Ambrosio P and Israel RJ: Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. ASCO Annu Meet Abstract no. 4662, 2012.
37. Antony GK, Dudek AZ: Interleukin 2 in cancer therapy. Curr Med Chem 17: 3297-3302, 2010.
38. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH: Clinical use of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen. J Urol 170: S84-88, 2003.
39. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L and Rosenberg SA: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105- 2116, 1999.
40. Rosenberg SA, Yang JC, White DE and Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg 228: 307-319, 1998.
41. Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O and Morse MA: Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu 14.18-1L2) in patients with metastatic malignant melanoma. J Transl Med 7: 68, 2009.
42. Tsuchiya Y, Yang ZB, Nakahashi S and Arika T: Acceleration of natural killer (NK) cell recovery by a glucan, sizofiran, in anti-asialoGM1 antibody-treated mice. Int J Immunopharmacol 15: 783-792, 1993.
43. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM and Tedder TF: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 12: 1659-1669, 2004.
44. Biburger M, Aschermann A, Schwab I, Lux A, Albert H, Danzer H, Woigk M, Dudziak D and Nimmerjahn F: Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932-944, 2011.
45. Nimmerjahn F and Ravetch JV: Fc¥ ã receptors as regulators of immune responses. Nature Rev Immunol 8: 34-47, 2008.